Erectile Dysfunction and Low Sex Drive in Men with Type 2 DM: The Potential Role of Diabetic Pharmacotherapy

Erectile Dysfunction and Low Sex Drive in Men with Type 2 DM: The Potential Role of Diabetic Pharmacotherapy

Introduction: Diabetic men with erectile dysfunction have not been widely studied. They have low testosterone levels, causing low sex drive and erectile dysfunction. Aim: To assess the erectile dysfunction and sex drive in relation to testosterone serum levels in type 2 Diabetes Mellitus (DM) p...

Full description

Bibliographic Details
Main Authors:	Hayder M. Al-Kuraishy, Ali I. Al-Gareeb
Format:	Article
Language:	English
Published:	JCDR Research and Publications Private Limited 2016-12-01
Series:	Journal of Clinical and Diagnostic Research
Subjects:	diabetic metformin sulfonylurea
Online Access:	https://jcdr.net/articles/PDF/8996/19971_CE(Ra1)_F(RK)_PF1(AHRK)_PFA(AK)_PF2(PAG).pdf

Similar Items

Initiation of insulin therapy in patients with type 2 diabetes: An observational study
by: Zerovnik Spela, et al.
Published: (2022-03-01)

Effects of diabetic pharmacotherapy on prolactin hormone in patients with type 2 diabetes mellitus: Bane or Boon
by: Huda Abdulbaki Rasheed, et al.
Published: (2019-01-01)

Comparison of the effectiveness of different oral glucose lowering drugs in fasting patients with type II diabetes
by: Mernoosh Zakerkish, et al.
Published: (2018-04-01)

REDUCTION OF CARDIOVASCULAR COMPLICATIONS OF MODERN HYPOGLYCEMIC THERAPY OF DIABETES MELLITUS TYPE 2: "FLORENTINE HERESY"
by: A. A. Aleksandrov
Published: (2016-01-01)

Predetermined Anti-Diabetic Drug Regimen Adjustments during Ramadan Fasting: An Observational Study of Safety
by: Abdallah M. Beano, et al.
Published: (2017-06-01)

Sulfonylurea and neuroprotection: The bright side of the moon
by: Nawar R Hussien, et al.
Published: (2018-01-01)

TREATMENT OF THE TYPE 2 OF DIABETES PATIENTS WITH THE SECONDARY FAILURE OF THE ORAL THERAPY: COMPARISON OF THE INSULIN-SULFONYLUREA REGIME AND THAT OF THE INSULIN-METFORMIN
by: Saša Živić, et al.
Published: (2002-09-01)

Effects of vildagliptin relative to sulfonylureas in Muslim patients with type 2 diabetes fasting during Ramadan: influence of age and treatment with/without metformin in the VIRTUE study
by: Hassoun AAK, et al.
Published: (2016-07-01)

Assessment of serum prolactin levels in acute myocardial infarction: The role of pharmacotherapy
by: Hayder M Al-Kuraishy, et al.
Published: (2016-01-01)

Risk of oncological diseases in patients with diabetes mellitus
by: Gagik Radikovich Galstyan
Published: (2009-12-01)

Fixed-dose combination in management of type 2 diabetes mellitus: Expert opinion from an international panel
by: Sanjay Kalra, et al.
Published: (2020-01-01)

Comparative evaluation of safety and efficacy of glimepiride and sitagliptin in combination with metformin in patients with type 2 diabetes mellitus: Indian multicentric randomized trial - START Study
by: T V Devarajan, et al.
Published: (2017-01-01)

Additional Effect of Dietary Fiber in Patients with Type 2 Diabetes Mellitus Using Metformin and Sulfonylurea: An Open-Label, Pilot Trial
by: Seung-Eun Lee, et al.
Published: (2019-08-01)

Endothelial dysfunction and inflammatory biomarkers as a response factor of concurrent coenzyme Q10 add-on metformin in patients with type 2 diabetes mellitus
by: Hayder M. Al-Kuraishy, et al.
Published: (2019-10-01)

Differential effect of metformin and/or glyburide on apelin serum levels in patients with type 2 diabetes mellitus: Concepts and clinical practice
by: Hayder M Al-Kuraishy, et al.
Published: (2018-01-01)

Prevalence of Hypoglycemia, Treatment Satisfaction, Adherence and Their Associations with Glycemic Goals in Patients with Type 2 Diabetes Mellitus Treated with Sulfonylureas: Findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) in Romania
by: Popoviciu Simona, et al.
Published: (2019-03-01)

Choice across 10 pharmacologic combination strategies for type 2 diabetes: a cost-effectiveness analysis
by: Shuyan Gu, et al.
Published: (2020-12-01)

Pharmacogenetics of Type 2 Diabetes—Progress and Prospects
by: Yulia A. Nasykhova, et al.
Published: (2020-09-01)

A Cohort Study of Antihyperglycemic Medication Exposure and Gastric Cancer Risk
by: Audrius Dulskas, et al.
Published: (2020-02-01)

Diabetes, Antidiabetic Medications and Cancer Risk in Type 2 Diabetes: Focus on SGLT-2 Inhibitors
by: Mariusz Dąbrowski
Published: (2021-02-01)

A Prospective Observational Study to Compare the Efficacy and Adverse Effects of Glimepiride and Vildagliptin Added to Metformin in Type 2 Diabetes Mellitus
by: Biswanath Sharma Sarkar, et al.
Published: (2019-02-01)

Erectile dysfunction and statins: The assorted view of preponderance
by: Hayder M Al-kuraishy, et al.
Published: (2020-01-01)

Evaluation of Receptor Activator of Nuclear Factor Kappa-B Ligand and Osteoprotegerin Levels in Patients with Type 2 Diabetes Mellitus Treated with Oral Anti-diabetics (Sulfonylurea and Metformin) or Insulin: Bone Tissue Perspective
by: Alper Gümüş, et al.
Published: (2019-03-01)

Beta-cell function in type 2 diabetic patients who failed to maintain good glycemic status with a combination of maximum dosages of metformin and sulfonylurea
by: Kunavisarut T, et al.
Published: (2019-05-01)

Type 2 diabetes therapy at the time of diagnosis. Glimepiride: property, efficiency, safety
by: Olga Mikhailovna Smirnova
Published: (2009-03-01)

Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
by: Se Hee Min, et al.
Published: (2015-12-01)

Association Between Diabetes Medications and the Risk of Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiaocui Qin, et al.
Published: (2021-07-01)

Preventive pharmacotherapy in type 2 diabetes mellitus
by: Neeraj Choudhary, et al.
Published: (2012-01-01)

Consensus recommendations on sulfonylurea and sulfonylurea combinations in the management of Type 2 diabetes mellitus – International Task Force
by: Sanjay Kalra, et al.
Published: (2018-01-01)

Transient neonatal diabetes mellitus caused by a gene mutation
by: Jung Hyun Kong, et al.
Published: (2011-04-01)

Effects of gliclazide add on metformin on serum omentin-1 levels in patients with type 2 diabetes mellitus
by: Ali I Al-Gareeb, et al.
Published: (2016-01-01)

Initial glucose-lowering therapy and risks of overall and cardiovascular mortality, myocardial infarction and stroke in patients with type2 diabetes
by: Inna Vladimirovna Misnikova, et al.
Published: (2009-12-01)

Genotypic and Phenotypic Factors Influencing Drug Response in Mexican Patients With Type 2 Diabetes Mellitus
by: Hector E. Sanchez-Ibarra, et al.
Published: (2018-04-01)

Recent Advances in Neonatal Diabetes
by: Dahl A, et al.
Published: (2020-02-01)

Prevalence of erectile dysfunction in Tehranian diabetic men
by: Alireza Mofid, et al.
Published: (2007-09-01)

The place of the third generation sulfonylurea glimepiride in modern therapy of type 2 diabetes mellitus
by: L.V. Zhuravlyova, et al.
Published: (2019-03-01)

Chronic heart failure in patients with type 2 diabetes mellitus: prevalence, prognosis
by: S. V Kakorin, et al.
Published: (2015-03-01)

Treatment of arterial hypertension in metabolic syndrome in men with erectile dysfunction
by: S. V. Nedogoda, et al.
Published: (2013-12-01)

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes
by: Morten Hindsø, et al.
Published: (2021-03-01)

Obesity and Erectile Dysfunction: From Bench to Clinical Implication
by: Ki Hak Moon, et al.
Published: (2019-05-01)